ZA200805822B - Compounds and methods for inhibiting the interaction of BCL proteins with binding partners - Google Patents

Compounds and methods for inhibiting the interaction of BCL proteins with binding partners

Info

Publication number
ZA200805822B
ZA200805822B ZA200805822A ZA200805822A ZA200805822B ZA 200805822 B ZA200805822 B ZA 200805822B ZA 200805822 A ZA200805822 A ZA 200805822A ZA 200805822 A ZA200805822 A ZA 200805822A ZA 200805822 B ZA200805822 B ZA 200805822B
Authority
ZA
South Africa
Prior art keywords
inhibiting
interaction
compounds
methods
binding partners
Prior art date
Application number
ZA200805822A
Other languages
English (en)
Inventor
Alfredo C Castro
Michael J Grogan
Edward B Holson
Brian T Hopkins
Nil O Koney
Peluso Stephane
Daniel A Snyder
Original Assignee
Infinity Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infinity Discovery Inc filed Critical Infinity Discovery Inc
Publication of ZA200805822B publication Critical patent/ZA200805822B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
ZA200805822A 2005-12-16 2008-07-03 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners ZA200805822B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75098705P 2005-12-16 2005-12-16

Publications (1)

Publication Number Publication Date
ZA200805822B true ZA200805822B (en) 2009-03-25

Family

ID=38024107

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200805822A ZA200805822B (en) 2005-12-16 2008-07-03 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners

Country Status (27)

Country Link
US (2) US7745464B2 (zh)
EP (1) EP1973875B1 (zh)
JP (1) JP5341521B2 (zh)
KR (1) KR101373911B1 (zh)
CN (1) CN101374807B (zh)
AR (1) AR058855A1 (zh)
AU (1) AU2006329879B2 (zh)
BR (1) BRPI0619968A2 (zh)
CA (1) CA2633958C (zh)
EC (1) ECSP088607A (zh)
ES (1) ES2494765T3 (zh)
HK (1) HK1119704A1 (zh)
IL (1) IL192023A (zh)
JO (1) JO2918B1 (zh)
MA (1) MA30144B1 (zh)
MX (1) MX2008007687A (zh)
MY (1) MY153232A (zh)
NO (1) NO20083050L (zh)
NZ (1) NZ569660A (zh)
PE (1) PE20071033A1 (zh)
RU (1) RU2424230C2 (zh)
SA (1) SA06270462B1 (zh)
SG (1) SG170727A1 (zh)
TN (1) TNSN08258A1 (zh)
TW (1) TWI403320B (zh)
WO (1) WO2007075387A1 (zh)
ZA (1) ZA200805822B (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842815B2 (en) * 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
TWI389895B (zh) * 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
US7858666B2 (en) 2007-06-08 2010-12-28 Mannkind Corporation IRE-1α inhibitors
CN101906056B (zh) * 2009-06-04 2013-10-30 中国科学院广州生物医药与健康研究院 作为m2抑制剂的环烷胺类化合物及其应用
US8314250B2 (en) * 2009-11-24 2012-11-20 Hoffmann-La Roche Inc. Sultam derivatives
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
FR3048698B1 (fr) * 2016-03-11 2021-03-05 Univ Claude Bernard Lyon Inhibiteurs de l'interaction bcl2 l10 / recepteur ip3
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR900012875A (ko) * 1989-02-08 1990-09-03 오스카 아끼히꼬 비페닐 유도체, 신경세포 변성수복 또는 보호제 및 여기에 사용되는 폐닐유도체의 제조방법
BR9408137A (pt) 1993-11-24 1997-08-12 Du Pont Merck Pharma Composto éster de prodroga método de tratamento composição farmacêutica e método de inibição
US6693123B2 (en) * 1995-11-06 2004-02-17 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
KR100399361B1 (ko) * 1999-11-04 2003-09-26 주식회사 엘지생명과학 캐스파제 억제제 함유 치료제 조성물
EP1125925A1 (en) * 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Amine derivatives for the treatment of apoptosis
AU2001252222B2 (en) * 2000-03-27 2006-11-02 Merck Serono Sa Pharmaceutically active pyrrolidine derivatives as bax inhibitors
AU2001284942A1 (en) 2000-08-16 2002-02-25 Georgetown University Medical Center Small molecule inhibitors targeted at bcl-2
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US7855183B2 (en) * 2000-11-10 2010-12-21 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US20040147473A1 (en) * 2000-11-10 2004-07-29 Warrell Raymond P. Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
DE60237115D1 (de) 2001-05-30 2010-09-02 Univ Georgetown Synergistische Kombination von (-) -Gossypol mit Docetaxel oder Paclitaxel zur Behandlung von Krebs.
US20030119894A1 (en) 2001-07-20 2003-06-26 Gemin X Biotechnologies Inc. Methods for treatment of cancer or neoplastic disease and for inhibiting growth of cancer cells and neoplastic cells
AU2003223708A1 (en) * 2002-04-23 2003-11-10 Axys Pharmaceuticals, Inc. Novel phenyl derivatives as inducers of apoptosis
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
MXPA05002573A (es) * 2002-09-04 2005-09-08 Schering Corp Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina.
JP2006516250A (ja) * 2002-12-18 2006-06-29 サイトビア インコーポレイティッド カスパーゼ活性化剤およびアポトーシス誘導物質としての３，５−二置換−［１，２，４］−オキサジアゾールおよびそれらの誘導体ならびにそれらの使用
US20040242886A1 (en) * 2003-04-30 2004-12-02 Sandeep Gupta Monocyclic diazodioxide based Bcl-2 protein antagonists related applications
CA2526387A1 (en) * 2003-06-12 2004-12-23 Astellas Pharma Inc. Benzamide derivative or salt thereof
WO2005026156A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives
ES2339670T3 (es) * 2003-12-23 2010-05-24 Novartis Ag Inhibidores heterociclicos biciclicos de la quinasa p-38.
TW200528101A (en) * 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
PL1768966T3 (pl) 2004-06-17 2012-08-31 Infinity Discovery Inc Związki i sposoby hamowania oddziaływania białek BCL z partnerami wiążącymi
WO2006025360A1 (ja) 2004-08-30 2006-03-09 Mitsubishi Rayon Co., Ltd. 光学用共重合体及びそれからなる成形体
TW200626142A (en) * 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
US7759337B2 (en) * 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
TW200803740A (en) * 2005-12-16 2008-01-16 Du Pont 5-aryl isoxazolines for controlling invertebrate pests
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
BRPI0619968A2 (pt) 2011-10-25
JP5341521B2 (ja) 2013-11-13
MA30144B1 (fr) 2009-01-02
EP1973875B1 (en) 2014-06-11
JP2009519946A (ja) 2009-05-21
WO2007075387A1 (en) 2007-07-05
SG170727A1 (en) 2011-05-30
TNSN08258A1 (en) 2009-10-30
KR101373911B1 (ko) 2014-03-12
CA2633958C (en) 2014-04-01
CN101374807A (zh) 2009-02-25
EP1973875A1 (en) 2008-10-01
NZ569660A (en) 2010-07-30
ES2494765T3 (es) 2014-09-16
US8304428B2 (en) 2012-11-06
SA06270462B1 (ar) 2011-10-03
CN101374807B (zh) 2013-10-09
TW200811100A (en) 2008-03-01
NO20083050L (no) 2008-09-10
JO2918B1 (en) 2015-09-15
MX2008007687A (es) 2008-09-26
AU2006329879A8 (en) 2008-08-07
AR058855A1 (es) 2008-02-27
MY153232A (en) 2015-01-29
TWI403320B (zh) 2013-08-01
AU2006329879A1 (en) 2007-07-05
HK1119704A1 (zh) 2009-03-13
RU2008128569A (ru) 2010-01-27
US20100190791A1 (en) 2010-07-29
PE20071033A1 (es) 2007-11-26
IL192023A (en) 2014-06-30
RU2424230C2 (ru) 2011-07-20
US7745464B2 (en) 2010-06-29
ECSP088607A (es) 2008-08-29
AU2006329879B2 (en) 2012-06-21
CA2633958A1 (en) 2007-07-05
US20070155705A1 (en) 2007-07-05
IL192023A0 (en) 2008-12-29
KR20080077017A (ko) 2008-08-20

Similar Documents

Publication Publication Date Title
IL197061A0 (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
HK1130057A1 (zh) 抑制 蛋白與結合伴侶交互作用的多種化合物和多個方法
HK1119704A1 (zh) 用於抑制 蛋白與結合配偶體相互作用的化合物和方法
IL189032A0 (en) Small compounds that correct protein misfolding and uses thereof
IL198872A0 (en) Igf-1r binding proteins and compositions containing the same
PT2343320T (pt) Anticorpos anti-gitr e as suas utilizações
EP1926485A4 (en) HIF-INHIBITORS
EP1868647A4 (en) OV064 BINDING ANTIBODIES AND METHOD FOR THEIR USE
IL181233A0 (en) Binding domain fusion proteins
EP1877079A4 (en) ELASTIN BINDING PROTEIN LIGANDS DERIVED FROM PLANTS AND METHODS OF USE
IL222922A (en) Antibodies against neurophilin-1 and their use
EP1846032A4 (en) LUCA2 AND ANTIBODY BINDING
HK1107402A1 (en) Kid31 and antibodies that bind thereto kid31
IL185309A0 (en) Isoqunoline compounds and methods of use thereof
EP1902066A4 (en) IL-6 BINDING PROTEINS
TWI350796B (en) Binder and its fastening member
EP1966603A4 (en) FIXING MOLECULES
IL185223A0 (en) Compounds and uses thereof
EP1877425A4 (en) FLUORESCENT PROTEINS AND ITS USE
EP1942012A4 (en) ATTACHED
GB0525380D0 (en) SRCR-B domain containing proteins
ZA200903440B (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
EP1915391A4 (en) SRA-BINDING PROTEIN
GB0511846D0 (en) Protein crystal
EP1935989A4 (en) METHOD FOR DETERMINING THE LENGTH OF THE SEQUENCE OF A TAIL G AND KIT FOR THE METHOD